Skip to Content
The biopharmaceutical company makes its debut on the Fortune 500 this year, riding the wave of a 49% year-over-year revenue increase in 2020—driven primarily by its cystic fibrosis drugs Kaftrio and Trikafta.
Lists ranking Vertex Pharmaceuticals
Fortune 500 - 2021This year’s Fortune 500 marks the 67th running of ...READ MOREview in list
Future 50 - 2020Explore this year's ranking of the 50 companies wi...READ MOREview in list
100 Fastest-Growing Companies - 2020Collectively, the ranked companies produced a thre...READ MOREview in list